Directions in antihypertensive treatment--our future from the past.
Future directions in antihypertensive treatment will rely on our present experience with antihypertensive drugs, on new concepts of cardiovascular regulation and on novel antihypertensive agents. At present, we seek early detection of hypertension; treatment should focus on normalization of blood pressure, the reversal or prevention of left ventricular hypertrophy, associated coronary artery disease and on the prevention of, or reparation of, myocardial fibrosis and microangiopathy. Therefore, combination therapy is advisable in severe cases, and any monotherapy should focus on the pharmacological principles compatible with these goals. ACE inhibitors and calcium antagonists appear to meet these requirements. There are, in addition, novel drugs i.e. angiotensin II receptor antagonists and renin inhibitors, as well as therapeutic stimulation of endothelial nitric oxide by L-arginine, the inhibition of endothelin-1 mediated vasoconstriction, and potassium-channel openers. All are examined in this contribution to delineate the perspectives in antihypertensive therapy.
Maisch
B
B
Department of Internal Medicine-Cardiology, Philipps-University Marburg, Germany.
Brilla
C
C
Kruse
T
T
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002309:Cardiology / Q000639:trends; D003094:Collagen / Q000378:metabolism; D048909:Diabetes Complications; D004359:Drug Therapy, Combination; D005109:Extracellular Matrix / Q000378:metabolism; D006321:Heart / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000473:pathology; D007333:Insulin Resistance; D009206:Myocardium / Q000378:metabolism; D009765:Obesity / Q000150:complications
D000959:Antihypertensive Agents; D003094:Collagen